Sutro Biopharma (STRO) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Voting matters and shareholder proposals
Election of three Class II directors: Jane Chung, Connie Matsui, and James Panek, with board recommending a vote for all nominees.
Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026, recommended for approval.
Advisory vote to approve compensation of named executive officers, with board recommending approval.
Board of directors and corporate governance
Board is seeking shareholder approval for the election of three Class II directors at the 2026 annual meeting.
Executive compensation and say-on-pay
Advisory vote on executive compensation is included, allowing shareholders to express approval or disapproval of named executive officer pay.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Sutro Biopharma
- Directors elected, auditor ratified, and executive pay approved; clinical goals accelerated.STRO
AGM 20265 Jun 2026 - Accelerated ADC pipeline and strong funding drive rapid clinical progress and upcoming data readout.STRO
Jefferies Global Healthcare Conference 20264 Jun 2026 - STRO-004 shows promise for broader solid tumor treatment with improved safety and efficacy.STRO
7th Annual Oncology Innovation Summit: Insights for ASCO & EHA28 May 2026 - Next-gen ADC platform delivers potent, differentiated therapies for major solid tumor indications.STRO
Corporate presentation14 May 2026 - Net loss narrowed to $38.5M on $14.5M revenue, with $202.6M cash and runway into Q2 2028.STRO
Q1 202614 May 2026 - Virtual meeting to elect directors, ratify auditor, and approve executive pay, with focus on governance.STRO
Proxy filing23 Apr 2026 - Next-gen ADCs advance with robust pipeline, dual-payload innovation, and strong clinical progress.STRO
Corporate presentation23 Apr 2026 - Next-generation ADCs advance toward key milestones, targeting major oncology markets with strong data.STRO
Corporate presentation24 Mar 2026 - Up to $300M in securities registered, including $100M ATM equity via TD Cowen for broad corporate use.STRO
Registration filing23 Mar 2026